Allergy to mould medication is an important topic for the many people in the UK who experience persistent sneezing, nasal congestion, itchy eyes, or worsening asthma triggered by fungal spores. Moulds such as Alternaria, Cladosporium, and Aspergillus release airborne spores both indoors and outdoors, provoking IgE-mediated immune responses in sensitised individuals. Managing mould allergy effectively requires understanding which medications are available, how they work, and when to seek further medical advice. This guide covers NHS-recommended treatments, their mechanisms, potential side effects, and the circumstances in which a GP or allergy specialist referral is warranted.

Understanding Mould Allergy and When Medication Is Needed

Mould allergy is an IgE-mediated immune response to inhaled fungal spores; medication is recommended when symptoms are persistent, moderate to severe, or significantly affect quality of life.

Mould allergy is an immune-mediated response triggered by the inhalation of fungal spores released by moulds such as Alternaria, Cladosporium, Aspergillus, and Penicillium. These spores are present both outdoors and indoors. Outdoor spore levels vary by species and weather conditions, with many peaking in late summer and autumn; however, indoor mould exposure can be persistent year-round, particularly in damp or poorly ventilated homes. When a sensitised individual inhales these spores, the immune system produces immunoglobulin E (IgE) antibodies, leading to the release of histamine and other inflammatory mediators.

Symptoms of mould allergy closely resemble those of other forms of allergic rhinitis and may include:

• Persistent sneezing and nasal congestion

• Itchy, watery, or red eyes (allergic conjunctivitis)

• Wheezing, coughing, or shortness of breath, particularly in those with co-existing asthma

• Skin reactions — atopic dermatitis (eczema) can flare in response to aeroallergens including mould spores; urticaria from inhaled moulds is less common and is not a typical presentation

Not everyone with mould sensitivity will require medication. Mild, infrequent symptoms may be managed through environmental control measures — such as improving ventilation, using extractor fans in kitchens and bathrooms, fixing leaks promptly, and addressing visible damp or water-damaged areas in the home. The UKHSA and NHS advise reducing indoor damp and condensation rather than targeting a specific humidity figure. However, when symptoms are persistent, moderate to severe, or significantly affect quality of life, pharmacological treatment becomes appropriate.

NICE CKS (Allergic rhinitis) and NHS guidance recommend a stepwise approach to management, beginning with over-the-counter remedies and escalating to prescription treatments where necessary. Early and consistent treatment is particularly important for individuals with asthma, as mould exposure is a recognised trigger for asthma exacerbations and, in rare cases, a condition called allergic bronchopulmonary aspergillosis (ABPA).

NHS-Recommended Medications for Mould Allergy

NICE CKS and BSACI guidance recommend intranasal corticosteroids as the most effective first-line treatment, with antihistamines, mast-cell stabilisers, montelukast, and immunotherapy used according to symptom severity and patient response.

NICE CKS (Allergic rhinitis) and BSACI/ARIA guidance recommend a structured approach to medication, tailored to symptom severity and patient preference. The principal treatment categories include antihistamines, intranasal corticosteroids, mast-cell stabilisers, and — in selected cases — leukotriene receptor antagonists or allergen immunotherapy.

Antihistamines are typically used for mild to moderate symptoms. Non-sedating oral antihistamines such as cetirizine, loratadine, and fexofenadine are available over the counter and are generally well tolerated. Antihistamine nasal sprays such as azelastine are available on prescription in the UK (azelastine nasal spray is not available over the counter) and may be used for localised nasal symptoms.

Mast-cell stabilisers — such as sodium cromoglicate eye drops — are used for ocular symptoms. Sodium cromoglicate is a mast-cell stabiliser, not an antihistamine, and works by preventing mast cells from releasing inflammatory mediators. It is available over the counter for allergic conjunctivitis.

Intranasal corticosteroids (INCs) — such as beclometasone, fluticasone, and mometasone — are considered the most effective first-line treatment for persistent or moderate-to-severe allergic rhinitis according to NICE CKS and BSACI guidance. They reduce local airway inflammation and are available both over the counter and on prescription. For best results, they should be used regularly rather than on an as-needed basis. A prescription-only combination intranasal spray containing azelastine and fluticasone is also available as a step-up option for patients with inadequately controlled symptoms.

Leukotriene receptor antagonists, such as montelukast, may be considered by a GP when antihistamines and INCs have not provided adequate relief or are not tolerated, particularly in patients with co-existing asthma. In line with MHRA advice (updated 2019 and 2022), montelukast should not be used as a first-line treatment for allergic rhinitis alone; its use should be restricted to patients who have not responded adequately to, or cannot tolerate, standard therapies. Montelukast carries an MHRA-mandated warning regarding potential neuropsychiatric side effects, and patients must be counselled accordingly before starting treatment.

Experiencing these side effects? Our pharmacists can help you navigate them →

Allergen immunotherapy (desensitisation) may be considered for patients with confirmed mould allergy who do not respond adequately to standard pharmacotherapy. It is specialist-initiated and supervised. It is important to note that licensed mould allergen extracts are limited, evidence for some mould species is less robust than for pollen or house dust mite, and patient selection is carefully considered by the specialist allergy team.

How Each Treatment Works and What to Expect

Antihistamines block H1 receptors within one to two hours, while intranasal corticosteroids require several days to two weeks of consistent use to reach full effect; immunotherapy is a long-term specialist intervention lasting three to five years.

Understanding the mechanism of action of each medication helps patients use them effectively and set realistic expectations about onset and duration of benefit.

Antihistamines work by competitively blocking H1 histamine receptors, thereby preventing histamine from binding and triggering the allergic response. Non-sedating antihistamines generally take effect within one to two hours and provide relief for up to 24 hours. They are particularly effective for sneezing, itching, and rhinorrhoea, but have limited impact on nasal congestion.

Intranasal corticosteroids act by suppressing the local inflammatory cascade within the nasal mucosa — reducing eosinophil infiltration, mast cell activity, and cytokine release. Unlike antihistamines, their full therapeutic effect may take several days to two weeks to become apparent, so patients should be advised to begin treatment before anticipated periods of increased exposure and to continue use consistently. Correct nasal spray technique — directing the nozzle away from the nasal septum and towards the outer wall of the nostril — is essential to maximise efficacy and minimise the risk of nosebleeds. The NHS provides patient guidance on correct nasal spray technique.

Montelukast blocks cysteinyl leukotriene receptors, reducing bronchoconstriction and nasal inflammation. It is taken once daily; for patients with co-existing asthma, evening dosing is generally preferred, but for allergic rhinitis alone the timing can be any consistent time of day, as per the product SmPC. Some improvement in rhinitis symptoms may be noticed within one day, with further benefit over several days of regular use. It is particularly useful in patients where both rhinitis and asthma require simultaneous management.

Immunotherapy works by gradually desensitising the immune system to specific mould allergens through repeated, controlled exposure — either via subcutaneous injections (SCIT) or sublingual drops or tablets (SLIT). This is a longer-term intervention, typically lasting three to five years, and is initiated and supervised exclusively by a specialist allergy clinic. Evidence and licensed extract availability vary by mould species; your specialist will advise on suitability.

Possible Side Effects and Safety Considerations

Intranasal corticosteroids are safe for long-term use with minimal systemic absorption; montelukast carries an MHRA-mandated neuropsychiatric warning and must be discontinued if mood or behavioural changes occur.

All medications carry a risk of side effects, and patients should be aware of what to monitor for when managing mould allergy pharmacologically.

Non-sedating antihistamines are generally well tolerated, but some individuals may still experience mild drowsiness, dry mouth, or headache. Even non-sedating antihistamines can impair alertness in some people; patients should avoid driving or operating machinery if they feel drowsy, and should avoid alcohol when taking sedating antihistamines. Always read the Patient Information Leaflet and consult a pharmacist or GP if you are unsure. Older, first-generation antihistamines such as chlorphenamine are more likely to cause sedation and anticholinergic effects and are not recommended for routine use in allergic rhinitis, particularly in elderly patients or those operating machinery.

Not sure if this is normal? Chat with one of our pharmacists →

Intranasal corticosteroids are considered safe for long-term use at recommended doses, as systemic absorption is minimal. However, common local side effects include:

• Nasal dryness or irritation

• Epistaxis (nosebleeds), which can often be minimised with correct technique

• Nasal crusting with prolonged use

Rarely, nasal septal perforation has been reported with long-term use. Patients using INCs alongside inhaled corticosteroids for asthma should inform their GP, as cumulative corticosteroid exposure should be monitored and reviewed periodically.

Montelukast carries an MHRA-mandated warning (updated 2019 and 2022) regarding neuropsychiatric reactions, including sleep disturbances, anxiety, depression, and suicidal ideation. Whilst these events are uncommon, patients and carers must be informed before initiation, and the medication should be discontinued if such symptoms emerge. Seek prompt medical advice if you notice any change in mood or behaviour.

Immunotherapy carries a small risk of systemic allergic reactions, including anaphylaxis, which is why subcutaneous immunotherapy must be administered in a clinical setting with resuscitation facilities available. Patients should remain under observation for at least 30 minutes post-injection.

If you experience a suspected side effect from any medication, you can report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app. Any unexpected or severe reactions should be reported promptly to a healthcare professional.

When to Seek Further Help From a GP or Allergy Specialist

Seek emergency care for signs of anaphylaxis or severe breathing difficulty; consult a GP if symptoms persist beyond two to four weeks of over-the-counter treatment, or if asthma is worsening or diagnosis is uncertain.

Whilst many cases of mould allergy can be managed effectively with over-the-counter treatments and environmental measures, there are important circumstances in which professional medical assessment is warranted.

Call 999 or go to your nearest A&E immediately if you experience:

• Severe difficulty breathing or chest tightness not responding to your reliever inhaler

• Swelling of the throat or tongue, hoarse voice, or stridor

• Dizziness, collapse, or loss of consciousness

• Signs of anaphylaxis (a severe, life-threatening allergic reaction)

Contact your GP if:

• Symptoms persist or worsen despite two to four weeks of appropriate over-the-counter treatment

• You experience frequent nosebleeds, significant nasal obstruction, or loss of smell

• You have unilateral (one-sided) nasal blockage or bleeding, which requires prompt assessment to exclude other causes

• Symptoms are significantly affecting sleep, work, or daily functioning

• You have co-existing asthma that appears to be worsening, particularly during damp seasons — review your asthma action plan with your GP or asthma nurse

• You are pregnant or breastfeeding and require medication guidance, as not all antihistamines or corticosteroids are suitable in these circumstances

• You experience any neuropsychiatric symptoms whilst taking montelukast

Referral to an NHS allergy specialist or ENT surgeon should be considered when:

• The diagnosis is uncertain and allergy testing (skin prick testing or specific IgE blood tests) is required to confirm mould sensitisation

• Symptoms are severe, poorly controlled, or associated with recurrent asthma exacerbations

• Immunotherapy is being considered as a treatment option

• There is a suspicion of allergic bronchopulmonary aspergillosis (ABPA), a more serious fungal hypersensitivity condition requiring specialist investigation and management

• Features suggest chronic rhinosinusitis, nasal polyps, or persistent anosmia, which may warrant ENT assessment

Environmental remediation — addressing damp, improving ventilation, and removing visible mould — remains a cornerstone of long-term management and should be pursued alongside any pharmacological treatment. The UKHSA and NHS provide guidance on managing damp and mould in the home. Patients concerned about mould in their home may also be entitled to support through their local council's environmental health team. Proactive management, combining medication with environmental control, offers the best outcomes for those living with mould allergy.

Frequently Asked Questions